{"id":59857,"date":"2025-07-12T15:10:10","date_gmt":"2025-07-12T15:10:10","guid":{"rendered":"https:\/\/www.europesays.com\/us\/59857\/"},"modified":"2025-07-12T15:10:10","modified_gmt":"2025-07-12T15:10:10","slug":"gene-key-to-ms-immune-regulation-discovered","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/59857\/","title":{"rendered":"Gene Key to MS Immune Regulation Discovered"},"content":{"rendered":"<p><strong>Summary: <\/strong>New research has identified the gene Egr-1 as a critical regulator of immune balance, offering hope for autoimmune disease therapies. In a mouse model of multiple sclerosis, loss of Egr-1 led to reduced regulatory T cell activity and heightened inflammation.<\/p>\n<p>The study showed Egr-1 directly boosts the expression of Foxp3, a protein essential for Treg cells, via the TGF-\u03b2 signaling pathway. Researchers also demonstrated that a natural compound, calycosin, can activate Egr-1, restoring Treg function and alleviating disease symptoms.<\/p>\n<p><strong>Key Facts:<\/strong><\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Egr-1 Role:<\/strong> Egr-1 enhances Foxp3 expression, strengthening regulatory T cells and reducing autoimmune inflammation.<\/li>\n<li><strong>Disease Link:<\/strong> Mice lacking Egr-1 showed more severe symptoms and fewer Treg cells in a model of multiple sclerosis.<\/li>\n<li><strong>Therapeutic Potential:<\/strong> The natural compound calycosin activated Egr-1, improving immune balance and disease outcomes.<\/li>\n<\/ul>\n<p><strong>Source: <\/strong>Research<\/p>\n<p><strong>Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect millions of people worldwide. <\/strong><\/p>\n<p>These conditions arise when the body\u2019s immune system fails to distinguish between \u201cself\u201d and \u201cforeign\u201d cells, and mistakenly attacks its own healthy cells, resulting in persistent inflammation and tissue damage.<\/p>\n<p>Central to these autoimmune responses are CD4+\u00a0T cells, a class of immune cells that can either promote or suppress the condition.<\/p>\n<p>  <img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"799\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/07\/immune-regulation-Ms-gene-neuroscienev.jpg\" alt=\"This shows DNA.\"  \/> After identifying Egr-1 as a regulatory gene, the team assessed its role by using genetically engineered mice lacking Egr-1 in CD4+ T cells. Credit: Neuroscience News<\/p>\n<p>Regulatory T cells (Treg) are a special subtype of CD4+\u00a0T cells that act as the immune system\u2019s peacekeepers. Treg\u00a0cells, marked by protein Foxp3, help in suppressing harmful immune responses.<\/p>\n<p>However, when the function of Treg\u00a0cells is compromised, as seen in cases of MS and IBD, the immune response is dominated by the Th1 and Th17 cells (other CD4+T cell subtypes), which promote inflammation, further worsening the disease symptoms.<\/p>\n<p>Therefore, boosting the development and activity of Treg\u00a0cells is emerging as a promising therapeutic approach, but the mechanisms underlying its effective regulation remain unclear.<\/p>\n<p>In pursuit of a deeper understanding of these mechanisms, a team of Chinese scientists led by Dr. Xiaojun Wu and Dr. Fei Huang from the Shanghai Key Laboratory of Compound Chinese Medicines, SHUTCM, China, and Dr. Weidong Pan from the Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China, explored the role of Early Growth Response Gene 1 (Egr-1) in promoting the activity of Treg\u00a0cells.<\/p>\n<p>The study was conducted in a well-established animal model of MS, called experimental autoimmune encephalomyelitis (EAE), to confirm the mechanisms.<\/p>\n<p>The findings of this study were published in Volume 8 of\u00a0Research\u00a0on April 15, 2025.<\/p>\n<p>Elaborating more, Dr. Wu, the lead author of this study, says \u201cWe started by screening the genes that appeared different between mice with mild and severe EAE.\u201d Further, he adds, \u201cAmong the top identified genes in CD4+\u00a0T cells,\u00a0Egr-1\u00a0stood out as significantly downregulated in severe disease.\u201d<\/p>\n<p>After identifying\u00a0Egr-1\u00a0as a regulatory gene, the team assessed its role by using genetically engineered mice lacking\u00a0Egr-1\u00a0in CD4+\u00a0T cells. These mice were induced with EAE and tracked for disease progression.<\/p>\n<p>The researchers also analyzed the immune cell compositions in the spleen, lymph nodes, and central nervous system of these mice.<\/p>\n<p>\u201cThe mice lacking\u00a0Egr-1\u00a0showed worse disease, fewer Treg\u00a0cells, and more inflammatory TH17 and TH1 cells\u201d explains Dr. Huang.<\/p>\n<p>The researchers also conducted additional\u00a0in vitro\u00a0experiments. By analyzing isolated human CD4+\u00a0T cells from MS patients and healthy donors, they confirmed that both\u00a0Egr-1\u00a0and\u00a0Foxp3\u00a0levels were reduced in patient samples. Further, to determine whether\u00a0Egr-1\u00a0directly regulates\u00a0Foxp3, the researchers used chromatin immunoprecipitation, which revealed that\u00a0Egr-1\u00a0binds to the\u00a0Foxp3\u00a0promoter.<\/p>\n<p>Additionally, using luciferase reporter assays, they also confirmed that\u00a0Egr-1\u00a0binding increases\u00a0Foxp3\u00a0gene activity. They then traced the pathway to TGF-\u03b2 (Transforming Growth Factor Beta) signaling via the Raf\/Mek\/Erk cascade, which activates\u00a0Egr-1.<\/p>\n<p>\u201cWe identified a unique mechanism of\u00a0Egr-1,\u201d\u00a0explains Dr. Pan, \u201cFirst, TGF-\u03b2 activates the Raf\/Mek\/Erk cascade, which activates\u00a0Egr-1.\u00a0Egr-1\u00a0then directly binds to the\u00a0Foxp3\u00a0promoter to enhance its expression, bypassing the classical Smad3-dependent pathway.\u201d<\/p>\n<p>What\u2019s more, the researchers also investigated the effect of a natural compound, Calycosin, which acts as an\u00a0Egr-1\u00a0agonist. Treatment with calycosin restored Treg\u00a0cell functions\u00a0and improve clinical outcomes in mice with EAE, but only in those with functional\u00a0Egr-1.<\/p>\n<p>Overall, the study underscores the essential role of\u00a0Egr-1\u00a0in Treg\u00a0cell development and function, identifying it as a central molecular switch in immune regulation.<\/p>\n<p>By elucidating its mechanism and validating the effect of a natural\u00a0Egr-1\u00a0agonist, the study suggests that targeting\u00a0Egr-1\u00a0may offer a promising treatment strategy, potentially transforming therapeutic approaches to autoimmune diseases.<\/p>\n<p>About this genetics and multiple sclerosis research news<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Author: <\/strong><a href=\"http:\/\/neurosciencenews.com\/cdn-cgi\/l\/email-protection#0f7b666e617b666e614f6c6e7c7b21607d68216c61\" target=\"_blank\" rel=\"noreferrer noopener\">Tian Tian<\/a><br \/><strong>Source: <\/strong><a href=\"https:\/\/cast.org.cn\" target=\"_blank\" rel=\"noreferrer noopener\">Research<\/a><br \/><strong>Contact: <\/strong>Tian Tian \u2013 Research<br \/><strong>Image: <\/strong>The image is credited to Neuroscience News<\/p>\n<p class=\"has-background\" style=\"background-color:#ffffe8\"><strong>Original Research: <\/strong>Open access.<br \/>\u201c<a href=\"https:\/\/dx.doi.org\/10.34133\/research.0662\" target=\"_blank\" rel=\"noreferrer noopener\">Early Growth Response Gene 1 Benefits Autoimmune Disease by Promoting Regulatory T Cell Differentiation as a Regulator of Foxp3<\/a>\u201d by Weidong Pan et al. Research<\/p>\n<p><strong>Abstract<\/strong><\/p>\n<p><strong>Early Growth Response Gene 1 Benefits Autoimmune Disease by Promoting Regulatory T Cell Differentiation as a Regulator of Foxp3<\/strong><\/p>\n<p>Foxp3+\u00a0regulatory T (Treg) cells, as one of the subtypes of CD4+\u00a0T cells, are the crucial gatekeeper in the pathogenesis of self-antigen reactive diseases.<\/p>\n<p>In this context, we demonstrated that the selective ablation of early growth response gene 1 (Egr-1) in CD4+\u00a0T cells exacerbated experimental autoimmune encephalomyelitis (EAE) in murine models.<\/p>\n<p>The absence of Egr-1 in CD4+\u00a0T cells, obtained from EAE mice and na\u00efve CD4+\u00a0T cells, impeded the differentiation and influence of Treg. Importantly, in CD4+\u00a0T cells of multiple sclerosis patients, both Egr-1 and Foxp3 were found to decrease.<\/p>\n<p>Further studies showed that distinct from the classical Smad3 route, TGF-\u03b2 could activate Egr-1 through the Raf\u2013Erk signaling route to promote Foxp3 genetic modulation, thereby promoting Treg\u00a0cell differentiation and reducing EAE inflammation.<\/p>\n<p>A novel natural Egr-1 agonist, calycosin, was found to attenuate EAE progression by regulating the differentiation of Treg.<\/p>\n<p>Together, the above results indicate the value of Egr-1, as a novel Foxp3 transactivator, for the differentiation of Treg\u00a0cells in the development of self-antigen reactive diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"Summary: New research has identified the gene Egr-1 as a critical regulator of immune balance, offering hope for&hellip;\n","protected":false},"author":3,"featured_media":59858,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[43460,827,43461,815,11834,43462,829,912,831,1183,159,67,132,68],"class_list":{"0":"post-59857","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-autoimmune-diseases","9":"tag-brain-research","10":"tag-egr-1","11":"tag-genetics","12":"tag-inflammation","13":"tag-multiple-sclerosis","14":"tag-neurobiology","15":"tag-neurology","16":"tag-neuroscience","17":"tag-research","18":"tag-science","19":"tag-united-states","20":"tag-unitedstates","21":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114840903627093180","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/59857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=59857"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/59857\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/59858"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=59857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=59857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=59857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}